In a clinical trial, the use of anthracycline for patients with ERBB2 (formerly HER2)-positive breast cancer in the presence of double ERBB2 blockade will increase the risk of febrile neutropenia and cardiotoxic effects (van der Voort et al., 2021). This evidence concerns the gene ERBB2 and breast carcinoma.